Wednesday, April 19, 2017

International Liver Congress 2017 - Early treatment of HCV reduces extrahepatic morbidity, mortality

Early treatment of HCV reduces extrahepatic morbidity, mortality
April 19, 2017
AMSTERDAM — Dealing with hepatitis C virus as a systemic disease, and not just a complication of the liver, may aid clinicians in reducing extrahepatic manifestations of the infection, according to experts at the International Liver Congress.

Francesco Negro, MD, of the departments of clinical pathology, gastroenterology and hepatology at University Hospital in Geneva, Switzerland, suggested that there is strong evidence that people with HCV often die of non–liver-related causes. “Of course, the leading cause of death is from the liver, but a group in Hong Kong observed many other reasons for dying, including renal, metabolic and cardiovascular disease,” he said. “These complications are not linked to the viral infection.”
Continue reading @ Healio

VIDEO: HCV elimination requires equitable care for injection drug users
AMSTERDAM — In this exclusive video from International Liver Congress, Jason Grebely, PhD, from the Kirby Institute at the University of New South Wales, Sydney, reviews strategies discussed at the conference for enhancing prevention and treatment of hepatitis C among people who inject drugs.
Continue reading @ Healio

Meeting Coverage Healio
International Liver Congress

International Liver Congress™ 2017
Updates On This Blog

No comments:

Post a Comment